Testing

In October 2019, Mayo Clinic Laboratories announced seven new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • November 7, 2019

This week’s featured chromosomal microarray test in focus is presented by William Sukov, M.D., a pathologist and cancer geneticist at Mayo Clinic. He discusses when this test should be used for patients with renal tumors.

By Alyssa Frank • October 17, 2019

In September 2019, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes. In addition to these new tests, the department also announced several test changes.

By Emily Linginfelter • October 3, 2019

Fewer than half the people found to have colorectal cancer are diagnosed at an early stage, when treatment is most effective. New therapies can reduce tumor size and prolong life, but they can also be costly and not work as intended. The results and interpretations from our laboratories provide clinically actionable results to guide treatment selection, ensuring every patient receives the medication most appropriate for care. In addition to guiding treatment, our testing also assesses risk for developing hereditary cancer syndrome.

By Alyssa Frank • October 2, 2019

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of August 2019.

By Molly Dee • September 27, 2019

The “Reject Due To” information contained in our online test catalog is being updated to provide greater clarity around rejection standards.

By Hannah Crawford • September 27, 2019

In August 2019, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • September 19, 2019

PD-L1 immunohistochemistry (IHC) is indicated in patients with specific tumor types in order to predict their responses to treatment with PD-L1 inhibitors. The specific PD-L1 clone, scoring method, and eligibility requirements are dependent on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor being considered.

By Alyssa Frank • September 15, 2019

With input from Mayo Clinic oncologists, our laboratories have developed a menu of next-generation sequencing (NGS) oncology panels. These panels aid in the diagnosis and management of patients with cancer and are optimized for clinically relevant genes and actionable targets consistent with current oncology guidelines.

By Alyssa Frank • September 1, 2019

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of July 2019.

By Molly Dee • August 27, 2019

In July 2019, Mayo Clinic Laboratories announced six new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • August 1, 2019

Ann Moyer, M.D., Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

By Emily Linginfelter • August 1, 2019

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of June 2019.

By Andy Tofilon • July 22, 2019